The breast is largely composed of glandular (apocrine) tissue surrounded by adipose tissue. This glandular tissue is made up of numerous milk producing lobules.
The endocrine system, including the pituitary gland, regulates mammary glands. Areolar and mammary glands are exocrine glands.
Mammary gland cells contain 'estrogen receptor alpha' (ER-α), 'progesterone receptor' (PR), and 'prolactin receptor' (PrLR) proteins.
Estradiol, progesterone and prolactin normally activate the respective receptors that cause breast growth. Estrogens, and progestogens are different categories of sex hormones. Prolactin is another type of hormone that reduces estrogen.
Activation of ER-α causes elongation or horizontal growth of mammary duct cells. PR, believed to be specific to 'Progesterone Receptor B' (PRB), activation causes side-branching of mammary gland cells. Density, Areolar gland development, and gland lactation development are caused by prolactin receptor activation.
Most breast development occurs during the luteal phase, usually days 14 to 28, which is associated with high levels of progesterone and a lesser but significant amount of estrogen. The luteal phase is signaled to start by luteinizing hormone (LH).
During the follicular phase, days 1 through 14, IGF-1 and prolactin are positively correlated with breast size. 'Insulin-like growth factor 1' (IGF-1) causes breast epithelial cell proliferation, and it may allow for breast size maintenance, and growth. Some hormones may be necessary for keeping gains made during the luteal phase.
Estrogen is normally high during ovulation (between menstruation and the luteal phase) and causes breast growth. Breast swelling during luteal phase is also growth, and perhaps antagonists undo this action that is associated with water weight. Progestins may possibly be ER-α antagonists, and estrogens might be PRB antagonists. Certain receptor antagonisms might be necessary to lessen desensitization, due to up or down regulation. However, an overload of antagonisms may damage receptors, desensitizing them.
References
* gland activation - Hormone Action in the Mammary Gland http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982168/
* mod - Botanical modulation of menopausal symptoms: Mechanisms of action? http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800090/
* endogenus - Breast Size in Relation to Endogenous Hormone Levels, Body Constitution, and Oral Contraceptive Use in Healthy Nulligravid Women Aged 19-25 Years http://aje.oxfordjournals.org/content/145/7/571.long
* mlpswelling - Breast: premenstrual tenderness and swelling http://www.nlm.nih.gov/medlineplus/ency/...003153.htm
The endocrine system, including the pituitary gland, regulates mammary glands.
Mammary gland cells contain 'estrogen receptor alpha' (ER-α), 'progesterone receptor' (PR), and 'prolactin receptor' (PrLR) proteins.
Estradiol, progesterone and prolactin normally activate the respective receptors that cause breast growth.
Activation of ER-α causes elongation or horizontal growth of mammary duct cells.
Most breast development occurs during the luteal phase, usually days 14 to 28, which is associated with high levels of progesterone and a lesser but significant amount of estrogen.
During the follicular phase, days 1 through 14, IGF-1 and prolactin are positively correlated with breast size.
Estrogen is normally high during ovulation (between menstruation and the luteal phase) and causes breast growth.
References
* gland activation - Hormone Action in the Mammary Gland http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982168/
* mod - Botanical modulation of menopausal symptoms: Mechanisms of action? http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800090/
* endogenus - Breast Size in Relation to Endogenous Hormone Levels, Body Constitution, and Oral Contraceptive Use in Healthy Nulligravid Women Aged 19-25 Years http://aje.oxfordjournals.org/content/145/7/571.long
* mlpswelling - Breast: premenstrual tenderness and swelling http://www.nlm.nih.gov/medlineplus/ency/...003153.htm